- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BIIB
Recent news which mentions BIIB
The 7 Most Promising Momentum Stocks to Own Now
August 31, 2023
From InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
August 30, 2023
From InvestorPlace
Better Buy: Biogen vs. Eli Lilly
August 29, 2023
From Motley Fool
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
August 28, 2023
From Motley Fool
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
August 24, 2023
From InvestorPlace
From Motley Fool
Why Shares of Sage Therapeutics Slumped This Week
August 11, 2023
From Motley Fool
Tickers
BIIB
From Motley Fool
With an Acquisition on the Way, Is Biogen Stock a Buy?
August 09, 2023
From Motley Fool
Is Sage Therapeutics a Contrarian Buy?
August 08, 2023
From Motley Fool
From Benzinga
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead
August 07, 2023
From Benzinga
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
August 07, 2023
From Benzinga
Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder
August 07, 2023
From MarketWatch
From Benzinga
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another
August 07, 2023
From Benzinga
From MarketWatch
3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now
August 02, 2023
From InvestorPlace
From InvestorPlace
From Motley Fool
Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer’s disease
July 31, 2023
From MarketWatch
From Benzinga
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
July 31, 2023
From Motley Fool
Could This Stock Be the Next Biotech Buyout?
July 31, 2023
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.